Soon to be revealed: latest EMA thinking on trial data disclosure
This article was originally published in SRA
In just over two weeks' time we will have a better idea of how the European Medicines Agency plans to implement its decision on the proactive publication of clinical trial data on authorized drugs, when it releases the recommendations of the five advisory groups set up following last year's workshop on trial data and transparency1.
You may also be interested in...
Coronavirus Notebook: Vaccine Shortage Fears Heightened By Safety Scares, Italian Jab Enters Phase II/III
Russia’s Sputnik V vaccine gets the all-clear in India as the COVAX initiative hits the shortages speed bump. Also, two more antibody treatments are OKd for use in COVID-19 in the UK.
The French authorities believe that the “heterologous prime-boost” approach is justified in the case of people aged under 55 years who are due to receive their second dose of the AZ COVID-19 vaccine.
Coronavirus Notebook: EMA Probes Janssen Vaccine Blood Clot Reports, UK Advises 12-Week Dosing Gap For Moderna
The AZ vaccine is now under EU scrutiny over capillary leak syndrome, while Valneva has reported positive results with its product. The global COVAX initiative has delivered more than 38 million doses of vaccines to over a hundred countries.